← Eichor
Condition: Gastric Cancer Stage Iii Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Gastric Cancer Stage Iii

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Phase III Clinical Study of Cadonilimab Plus SOX as Perioperative Treatment for Patients With Resectable G/GEJ Adenoca
Phase 3 · 6 location(s) · Akeso · NCT07023315Tislelizumab Plus FOLFOX Versus POF in the Treatment of Locally Advanced: a Multicenter, Open-label, Randomized Phase II
Phase 3 · 1 location(s) · Fujian Cancer Hospital · NCT06793917DV Combined With Cadonilimab in Subjects With HER2-expressing Gastric Cancer and Gastroesophageal Junction Adenocarcinom
Phase 2/Phase 3 · 12 location(s) · RemeGen Co., Ltd. · NCT06221748Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Meta
Phase 3 · 286 location(s) · AstraZeneca · NCT07431281A Phase III Randomized Study in CLDN18.2-positive Unresectable Locally Advanced Gastric Cancer Patients
Phase 3 · 1 location(s) · Suzhou Immunofoco Biotechnology Co., Ltd · NCT07103668Investigation of Impact of Indocyanine Green on Volume of Lymphadenectomy in Resectable Gastric Cancer
Phase 3 · 2 location(s) · Ukrainian Society of Clinical Oncology · NCT06755554Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab and Tislelizumab Combined Chemo
Phase 3 · 106 location(s) · Shanghai Chia Tai Tianqing Pharmaceutical Technology Develop · NCT07385703Adjuvant Serplulimab and Trastuzuma and Chemotherapy in Her-2+ Gastric Cancer
Phase 2 · 1 location(s) · Fudan University · NCT05975749Study of Adjuvant Chemotherapy With or Without PD-1 Inhibitors and Chemoradiotherapy in Resected pN3 Gastric (G) or GEJ
Phase 3 · 1 location(s) · Fudan University · NCT04997837Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic Oeso-gastric Adenocarcinoma
Phase 3 · 64 location(s) · Federation Francophone de Cancerologie Digestive · NCT07270991Testing the Combination of the Anticancer Drugs Trastuzumab Deruxtecan (DS-8201a) and Azenosertib (ZN-c3) in Patients Wi
Phase 1 · 1 location(s) · National Cancer Institute (NCI) · NCT06364410A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus Chemotherapy Combined With Trastuzumab Wi
Phase 3 · 1 location(s) · RemeGen Co., Ltd. · NCT07315750A Multicenter, RCT Study of the Clinical Efficacy of Robotic and Laparoscopic Gastrectomy in Neoadjuvant Gastric Cancer
NA · 1 location(s) · The Affiliated Hospital of Qingdao University · NCT06042998Adjuvant Capecitabine Versus Observation Alone in Curatively Resected Stage IB Gastric Cancer((KCSG ST14-05): CATALYSIS
Phase 3 · 1 location(s) · Asan Medical Center · NCT01917552Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET
Phase 3 · 65 location(s) · Novartis Pharmaceuticals · NCT06784752HIPEC + FLOT vs. FLOT Alone in Patients With Gastric Cancer and GEJ (PREVENT)
Phase 3 · 15 location(s) · Krankenhaus Nordwest · NCT04447352Testing the Addition of Paclitaxel Administered Into the Abdominal Cavity Combined With Chemotherapy for Patients With G
Phase 2/Phase 3 · 55 location(s) · ECOG-ACRIN Cancer Research Group · NCT07001748Metronomic Capecitabine in Stage III Gastric Cancer
Phase 3 · 1 location(s) · Fudan University · NCT06313567PIPAC in Multimodal Therapy for Patients with Oligometastatic Peritoneal Gastric Cancer
Phase 3 · 1 location(s) · Azienda Ospedaliera Universitaria Integrata Verona · NCT05303714mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Neg
Phase 3 · 794 location(s) · Alliance for Clinical Trials in Oncology · NCT05677490To Evaluate IAH0968 in Combination With CAPEOX in HER2-positive Gastric Cancer
Phase 2/Phase 3 · 2 location(s) · SUNHO（China）BioPharmaceutical CO., Ltd. · NCT06504732Optimal Duration of Oxaliplatin in Adjuvant XELOX for Gastric Cancer Patients (EXODOX)
Phase 3 · 1 location(s) · Hallym University Medical Center · NCT04787354PD-1 Antibody Carilizumab Combined with Apatinib for Unresectable Stage III and IV DMMR Gastric Cancer
Phase 2 · 1 location(s) · Peking University Third Hospital · NCT06792162Clinical Study of Adebrelimab Therapy in the Perioperative Treatment of Gastric Cancer or Gastroesophageal Junction Canc
Phase 3 · 1 location(s) · Shanghai Shengdi Pharmaceutical Co., Ltd · NCT07522151Oxaliplatin Combined With S-1(SOX) Neoadjuvant Chemotherapy for Different Cycles in Patients With Gastric Cancer
Phase 3 · 1 location(s) · Chinese PLA General Hospital · NCT04483076Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer
Phase 3 · 5 location(s) · Ruijin Hospital · NCT07366528Intraperitoneal Paclitaxel and Systemic Therapy Versus Systemic Therapy Alone in Gastric Cancer Patients With Peritoneal
Phase 3 · 7 location(s) · Magnus Nilsson · NCT07304271Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes
NA · 1 location(s) · Cedars-Sinai Medical Center · NCT04907643Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors
Phase 1/Phase 2 · 1 location(s) · Mayo Clinic · NCT05269381Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma
Phase 2 · 1 location(s) · The First Affiliated Hospital with Nanjing Medical Universit · NCT07277439
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.